Effect of a leukotriene receptor antagonist, pranlukast hydrate, on airway inflammation and airway hyperresponsiveness in patients with moderate to severe asthma

Allergology International

Volumn 49, Issue 1, 2000, Pages 63-68

  Wada, Kiyoko ^a   Minoguchi, Kenji ^a,b   Kohno, Yasurou ^a   Oda, Naruhito ^a   Matsuura, Takayuki ^a   Kawazu, Kenta ^a   Kurokawa, Masatsugu ^a   Tomita, Takeshi ^a   Ueno, Kana ^a   Kokubu, Fumio ^a   Mita, Shunichi ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airway hyperresponsiveness; Airway inflammation; Asthma; Eosinophils; Leukotriene; Leukotriene receptor antagonist

Indexed keywords

PRANLUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LEUKOCYTE MIGRATION; LUNG FUNCTION; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

EID: 6744257506     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2000.00160.x     Document Type: Article

References (29)

1. Poston RN, Chanez P, Lacoste JY et al. Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. Am. Rev. Respir. Dis. 1992; 145: 918-21.
2. O'Byrine PM, Hargreeve FE, Kirby JG. Airway inflammation and hyperresponsiveness. Am. Rev. Respir. Dis. 1987; 136: S35-7.
3. Drazen JM, Israel E, O'Byrine PM. Treatment of asthma with drug modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340: 197-206.
4. Feldberg W, Kellaway CH. Liberation of histamine and formation of lyscithin-like substances by cobra venom. J. Physiol. 1938; 94: 187-226.
5. Samuelsson B. Leukotrienes: Mediators of hypersensitivity reactions and inflammation. Science 1983; 220: 568-75.
6. Weller PF, Lee CW, Foster DW et al. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: Predominant production of leukotriene C4. Proc. Natl Acad. Sci. USA 1983; 80: 7626-30.
7. Chung KF, Holgate ST. Leukotrienes: Why are they important mediators in asthma? Eur. Respir. J. 1997; 7: 259-63.
8. Wenzel SE, Larsen GL, Johnston K et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 1990; 142: 112-19.
9. Taylor GW, Taylor I, Blacke P et al. Urinary leukotriene-FA after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; i: 584-8.
10. Drazen JM, O'Brien J, Sparrow D et al. Recovery of leukotriene-E4 from the urine of patients with airway obstruction. Am. Rev. Respir. Dis. 1992; 146: 104-8.
11. Okudaira H. Challenge studies of an LT receptor antagonist. Chest 1997; 111: S46-51.
12. Hirata K, Kurihara N, Kamimoni T et al. Exercise-induced asthma and leukotriene antagonists. J. Clin. Ther. Med. 1993; 9: 225-8.
13. Strek ME, Sedy J, Solway J et al. Pranlukast inhibits cold-air-induced bronchoconstriction in patients with asthma. J. Allergy Clin, Immunol. 1997; 99: 329.
14. Yamamoto H, Nagata M, Kuramitu K et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am. J. Respir. Crit. Care Med. 1994; 150: 254-7.
15. Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J. Allergy Clin. Immunol. 1998; 102: 927-34.
16. Makino S, Kobayashi S, Miyamoto T et al. Standard methods of provocation tests for asthma and hypersensitivity pneumonitis. Jpn. J. Allergol. 1982; 31: 1074-6.
17. Peterson CGB, Enander I, Nystrand J et al. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method: Establishment of normal levels in serum and turnover in vivo. Clin. Exp. Allergy 1991; 21: 561-7.
18. Bousquet J, Chanez P, Chanal I et al. Comparison between RAST and Pharmacia CAP system: A new automated specific IgE assay. J. Allergy Clin. Immunol. 1990; 85: 1039-43.
19. Japanese Society of Allergology Committee on the Definition, Treatment and Management of Bronchial Asthma. Guideline for the diagnosis and management of bronchial asthma. Allergy 1995; 50 (Suppl. 1): S1-41.
20. National Asthma Education Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. National Institutes of Health Pub. no. 97-4051. Bethesda, MD 1997.
21. British Thoracic Society. The British Guidelines on Asthma Management 1995 Review and Position Statement. Thorax 1995; 52 (Suppl. 1): SI-21.
22. Imai T, Okamoto M, Horikoshi S et al. Chemotactic activity of human peripheral eosinophils toward leukotriene E4. Jpn. J. Allergol. 1997; 46: 609-11.
23. Czarnetzki BM, Csato M. Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4. Int. Arch. Allergy Immunol. 1989; 88: 191-3.
24. Laitinen LA, Laitinen A, Haahtela T et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989-90.
25. Minoguchi K, Kohno Y, Kobayashi H et al. Potential anti-inflammatory effect of montelukast on airway in asthmatics. Eur. Respir. J. 14 (Suppl. 30): 121.
26. Arm JP, Spur BW, Lee TH. The effect of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J. Allergy Clin. Immunol. 1988;82:654-60.
27. O'Hickey SP, Hawksworth RJ, Fong CY et al. Leukotriene C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am. Rev. Respir. Dis. 1991; 144: 1053-7.
28. Fujimura M, Sakamoto S, Kamio Y et al. Effect of leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir. Med. 1993; 87: 133-8.
29. Israel E, Dermarkarian R, Rosenberg M et al. The effect of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N. Engl. J. Med. 1990; 323: 1740-4.